View ValuationZentiva 将来の成長Future 基準チェック /06現在、 Zentivaの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長10.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • Nov 17Third quarter 2024 earnings released: EPS: RON0.085 (vs RON0.074 in 3Q 2023)Third quarter 2024 results: EPS: RON0.085 (up from RON0.074 in 3Q 2023). Revenue: RON273.7m (up 17% from 3Q 2023). Net income: RON59.0m (up 14% from 3Q 2023). Profit margin: 22% (in line with 3Q 2023). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.New Risk • Nov 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Romanian stocks, typically moving 5.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Reported Earnings • Sep 03Second quarter 2024 earnings released: EPS: RON0.099 (vs RON0.043 in 2Q 2023)Second quarter 2024 results: EPS: RON0.099 (up from RON0.043 in 2Q 2023). Revenue: RON285.0m (up 30% from 2Q 2023). Net income: RON68.9m (up 132% from 2Q 2023). Profit margin: 24% (up from 14% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth.分析記事 • Jul 30Take Care Before Diving Into The Deep End On Zentiva S.A. (BVB:SCD)When close to half the companies in Romania have price-to-earnings ratios (or "P/E's") above 17x, you may consider...Valuation Update With 7 Day Price Move • Jul 29Investor sentiment improves as stock rises 17%After last week's 17% share price gain to RON4.16, the stock trades at a trailing P/E ratio of 12.9x. Average trailing P/E is 27x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 56% over the past three years.Reported Earnings • May 19First quarter 2024 earnings released: EPS: RON0.11 (vs RON0.061 in 1Q 2023)First quarter 2024 results: EPS: RON0.11 (up from RON0.061 in 1Q 2023). Revenue: RON266.3m (up 15% from 1Q 2023). Net income: RON74.2m (up 74% from 1Q 2023). Profit margin: 28% (up from 19% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.Reported Earnings • Mar 03Full year 2023 earnings released: EPS: RON0.27 (vs RON0.14 in FY 2022)Full year 2023 results: EPS: RON0.27 (up from RON0.14 in FY 2022). Revenue: RON945.7m (up 25% from FY 2022). Net income: RON191.1m (up 92% from FY 2022). Profit margin: 20% (up from 13% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.分析記事 • Mar 02Zentiva S.A. (BVB:SCD) Doing What It Can To Lift SharesThere wouldn't be many who think Zentiva S.A.'s ( BVB:SCD ) price-to-earnings (or "P/E") ratio of 11.6x is worth a...New Risk • Nov 17New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 23% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 15% per year over the past 5 years. High level of non-cash earnings (23% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (5.9% average weekly change).Reported Earnings • Nov 17Third quarter 2023 earnings released: EPS: RON0.074 (vs RON0.003 in 3Q 2022)Third quarter 2023 results: EPS: RON0.074 (up from RON0.003 in 3Q 2022). Revenue: RON233.9m (up 33% from 3Q 2022). Net income: RON51.5m (up RON49.7m from 3Q 2022). Profit margin: 22% (up from 1.0% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Nov 15Investor sentiment improves as stock rises 17%After last week's 17% share price gain to RON2.78, the stock trades at a trailing P/E ratio of 13.8x. Average trailing P/E is 22x in the Pharmaceuticals industry in Europe. Negligible returns to shareholders over past three years.Reported Earnings • Sep 03Second quarter 2023 earnings released: EPS: RON0.043 (vs RON0.038 in 2Q 2022)Second quarter 2023 results: EPS: RON0.043 (up from RON0.038 in 2Q 2022). Revenue: RON219.9m (up 14% from 2Q 2022). Net income: RON29.6m (up 11% from 2Q 2022). Profit margin: 14% (in line with 2Q 2022). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.New Risk • Aug 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Romanian stocks, typically moving 5.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 17% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (5.3% average weekly change).New Risk • Jun 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Romanian stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 17% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (5.4% average weekly change).Reported Earnings • May 18First quarter 2023 earnings released: EPS: RON0.061 (vs RON0.007 in 1Q 2022)First quarter 2023 results: EPS: RON0.061 (up from RON0.007 in 1Q 2022). Revenue: RON230.7m (up 36% from 1Q 2022). Net income: RON42.7m (up RON37.8m from 1Q 2022). Profit margin: 19% (up from 2.9% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 31Full year 2022 earnings released: EPS: RON0.14 (vs RON0.15 in FY 2021)Full year 2022 results: EPS: RON0.14 (down from RON0.15 in FY 2021). Revenue: RON759.6m (up 6.9% from FY 2021). Net income: RON99.5m (down 5.9% from FY 2021). Profit margin: 13% (down from 15% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 18Third quarter 2022 earnings released: EPS: RON0.003 (vs RON0.02 in 3Q 2021)Third quarter 2022 results: EPS: RON0.003 (down from RON0.02 in 3Q 2021). Revenue: RON175.4m (up 1.5% from 3Q 2021). Net income: RON1.83m (down 87% from 3Q 2021). Profit margin: 1.0% (down from 8.0% in 3Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Francois Marchand was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Sep 06Second quarter 2022 earnings released: EPS: RON0.038 (vs RON0.016 in 2Q 2021)Second quarter 2022 results: EPS: RON0.038 (up from RON0.016 in 2Q 2021). Revenue: RON193.4m (up 16% from 2Q 2021). Net income: RON26.8m (up 145% from 2Q 2021). Profit margin: 14% (up from 6.6% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.Board Change • Apr 28Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Francois Marchand was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Mar 04Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: RON0.14 (up from RON0.094 in FY 2020). Revenue: RON694.8m (up 25% from FY 2020). Net income: RON94.7m (up 44% from FY 2020). Profit margin: 14% (up from 12% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 60 percentage points per year, which is a significant difference in performance.Reported Earnings • Nov 18Third quarter 2021 earnings released: EPS RON0.02 (vs RON0.017 in 3Q 2020)The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: RON172.7m (up 26% from 3Q 2020). Net income: RON13.8m (up 20% from 3Q 2020). Profit margin: 8.0% (down from 8.4% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance.Reported Earnings • Sep 03Second quarter 2021 earnings released: EPS RON0.016 (vs RON0.011 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: RON167.2m (up 30% from 2Q 2020). Net income: RON11.0m (up 41% from 2Q 2020). Profit margin: 6.6% (up from 6.1% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.Board Change • Jul 28Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Francois Marchand was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.分析記事 • May 24Zentiva's (BVB:SCD) Solid Earnings May Rest On Weak FoundationsThe recent earnings posted by Zentiva S.A. ( BVB:SCD ) were solid, but the stock didn't move as much as we expected. We...Reported Earnings • May 19First quarter 2021 earnings released: EPS RON0.034 (vs RON0.049 in 1Q 2020)The company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2021 results: Revenue: RON163.1m (up 6.5% from 1Q 2020). Net income: RON23.6m (down 31% from 1Q 2020). Profit margin: 14% (down from 22% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.Reported Earnings • Mar 03Full year 2020 earnings released: EPS RON0.088 (vs RON0.082 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: RON602.3m (up 7.7% from FY 2019). Net income: RON61.3m (up 40% from FY 2019). Profit margin: 10% (up from 7.8% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.分析記事 • Mar 01Zentiva (BVB:SCD) Has Gifted Shareholders With A Fantastic 201% Total Return On Their InvestmentPassive investing in index funds can generate returns that roughly match the overall market. But the truth is, you can...お知らせ • Jan 29Nanologica AB (publ) Signs Collaboration Agreement with Zentiva for the Use of Nlab Drug Delivery PlatformsNanologica AB (publ) announced a collaboration agreement for the use of the NLAB drug delivery platforms has been signed with Zentiva, a pharmaceutical company operating in Europe and beyond. The aim of this collaboration agreement is to simplify the contract process for future product-specific agreements. The agreement gives Zentiva the right to use the NLAB drug delivery platforms for multiple drug development projects. Project specific agreements will be signed separately under this collaboration agreement. Zentiva is a producer of high-quality and affordable medicines, serving people in Europe and beyond. The Company headquartered in Prague, Czech Republic has a network of productions sites and employs more than 4 500 employees.分析記事 • Jan 25Zentiva S.A.'s (BVB:SCD) Stock Is Going Strong: Have Financials A Role To Play?Most readers would already be aware that Zentiva's (BVB:SCD) stock increased significantly by 11% over the past three...Is New 90 Day High Low • Jan 14New 90-day high: RON2.98The company is up 6.0% from its price of RON2.82 on 16 October 2020. The Romanian market is up 16% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 1.0% over the same period.分析記事 • Dec 18Zentiva S.A. (BVB:SCD) Investors Are Less Pessimistic Than ExpectedWhen close to half the companies in Romania have price-to-earnings ratios (or "P/E's") below 12x, you may consider... このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Zentiva は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測BVB:SCD - アナリストの将来予測と過去の財務データ ( )RON Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/20241,0942714285N/A6/30/20241,0542633982N/A3/31/20249892242665N/A12/31/2023954193-1414N/A9/30/2023906190-48-21N/A6/30/2023848140-167N/A3/31/2023821137-521N/A12/31/202276099-721N/A9/30/202274691203230N/A6/30/2022743103163188N/A3/31/202271787213236N/A12/31/2021711106168191N/A9/30/202164361-48-21N/A6/30/202160758-211N/A3/31/202156855-51-26N/A12/31/2020558661843N/A9/30/2020572384279N/A6/30/202055664-1126N/A3/31/202056345-37-4N/A12/31/201955944-56-21N/A9/30/201955476N/AN/AN/A6/30/2019524248229256N/A3/31/2019504282N/AN/AN/A12/31/2018461263240262N/A9/30/2018446269N/AN/AN/A6/30/201845283N/A71N/A3/31/201845584N/AN/AN/A12/31/201745890N/A110N/A9/30/201744987N/AN/AN/A6/30/201745584N/A98N/A3/31/201743071N/AN/AN/A12/31/201642073N/A169N/A9/30/201640960N/AN/AN/A6/30/201641361N/A60N/A3/31/201640754N/AN/AN/A12/31/201539746N/A48N/A9/30/201536750N/AN/AN/A6/30/201537245N/AN/AN/A3/31/201538252N/AN/AN/A12/31/201439455N/A41N/A9/30/201436446N/AN/AN/A6/30/201432839N/AN/AN/A3/31/201431941N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: SCDの予測収益成長が 貯蓄率 ( 6.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: SCDの収益がRO市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: SCDの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: SCDの収益がRO市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: SCDの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: SCDの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/02/17 21:31終値2024/11/20 00:00収益2024/09/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Zentiva S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Nov 17Third quarter 2024 earnings released: EPS: RON0.085 (vs RON0.074 in 3Q 2023)Third quarter 2024 results: EPS: RON0.085 (up from RON0.074 in 3Q 2023). Revenue: RON273.7m (up 17% from 3Q 2023). Net income: RON59.0m (up 14% from 3Q 2023). Profit margin: 22% (in line with 3Q 2023). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.
New Risk • Nov 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Romanian stocks, typically moving 5.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Reported Earnings • Sep 03Second quarter 2024 earnings released: EPS: RON0.099 (vs RON0.043 in 2Q 2023)Second quarter 2024 results: EPS: RON0.099 (up from RON0.043 in 2Q 2023). Revenue: RON285.0m (up 30% from 2Q 2023). Net income: RON68.9m (up 132% from 2Q 2023). Profit margin: 24% (up from 14% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth.
分析記事 • Jul 30Take Care Before Diving Into The Deep End On Zentiva S.A. (BVB:SCD)When close to half the companies in Romania have price-to-earnings ratios (or "P/E's") above 17x, you may consider...
Valuation Update With 7 Day Price Move • Jul 29Investor sentiment improves as stock rises 17%After last week's 17% share price gain to RON4.16, the stock trades at a trailing P/E ratio of 12.9x. Average trailing P/E is 27x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 56% over the past three years.
Reported Earnings • May 19First quarter 2024 earnings released: EPS: RON0.11 (vs RON0.061 in 1Q 2023)First quarter 2024 results: EPS: RON0.11 (up from RON0.061 in 1Q 2023). Revenue: RON266.3m (up 15% from 1Q 2023). Net income: RON74.2m (up 74% from 1Q 2023). Profit margin: 28% (up from 19% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Mar 03Full year 2023 earnings released: EPS: RON0.27 (vs RON0.14 in FY 2022)Full year 2023 results: EPS: RON0.27 (up from RON0.14 in FY 2022). Revenue: RON945.7m (up 25% from FY 2022). Net income: RON191.1m (up 92% from FY 2022). Profit margin: 20% (up from 13% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
分析記事 • Mar 02Zentiva S.A. (BVB:SCD) Doing What It Can To Lift SharesThere wouldn't be many who think Zentiva S.A.'s ( BVB:SCD ) price-to-earnings (or "P/E") ratio of 11.6x is worth a...
New Risk • Nov 17New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 23% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 15% per year over the past 5 years. High level of non-cash earnings (23% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (5.9% average weekly change).
Reported Earnings • Nov 17Third quarter 2023 earnings released: EPS: RON0.074 (vs RON0.003 in 3Q 2022)Third quarter 2023 results: EPS: RON0.074 (up from RON0.003 in 3Q 2022). Revenue: RON233.9m (up 33% from 3Q 2022). Net income: RON51.5m (up RON49.7m from 3Q 2022). Profit margin: 22% (up from 1.0% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Nov 15Investor sentiment improves as stock rises 17%After last week's 17% share price gain to RON2.78, the stock trades at a trailing P/E ratio of 13.8x. Average trailing P/E is 22x in the Pharmaceuticals industry in Europe. Negligible returns to shareholders over past three years.
Reported Earnings • Sep 03Second quarter 2023 earnings released: EPS: RON0.043 (vs RON0.038 in 2Q 2022)Second quarter 2023 results: EPS: RON0.043 (up from RON0.038 in 2Q 2022). Revenue: RON219.9m (up 14% from 2Q 2022). Net income: RON29.6m (up 11% from 2Q 2022). Profit margin: 14% (in line with 2Q 2022). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
New Risk • Aug 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Romanian stocks, typically moving 5.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 17% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (5.3% average weekly change).
New Risk • Jun 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Romanian stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 17% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (5.4% average weekly change).
Reported Earnings • May 18First quarter 2023 earnings released: EPS: RON0.061 (vs RON0.007 in 1Q 2022)First quarter 2023 results: EPS: RON0.061 (up from RON0.007 in 1Q 2022). Revenue: RON230.7m (up 36% from 1Q 2022). Net income: RON42.7m (up RON37.8m from 1Q 2022). Profit margin: 19% (up from 2.9% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 31Full year 2022 earnings released: EPS: RON0.14 (vs RON0.15 in FY 2021)Full year 2022 results: EPS: RON0.14 (down from RON0.15 in FY 2021). Revenue: RON759.6m (up 6.9% from FY 2021). Net income: RON99.5m (down 5.9% from FY 2021). Profit margin: 13% (down from 15% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 18Third quarter 2022 earnings released: EPS: RON0.003 (vs RON0.02 in 3Q 2021)Third quarter 2022 results: EPS: RON0.003 (down from RON0.02 in 3Q 2021). Revenue: RON175.4m (up 1.5% from 3Q 2021). Net income: RON1.83m (down 87% from 3Q 2021). Profit margin: 1.0% (down from 8.0% in 3Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Francois Marchand was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Sep 06Second quarter 2022 earnings released: EPS: RON0.038 (vs RON0.016 in 2Q 2021)Second quarter 2022 results: EPS: RON0.038 (up from RON0.016 in 2Q 2021). Revenue: RON193.4m (up 16% from 2Q 2021). Net income: RON26.8m (up 145% from 2Q 2021). Profit margin: 14% (up from 6.6% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.
Board Change • Apr 28Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Francois Marchand was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Mar 04Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: RON0.14 (up from RON0.094 in FY 2020). Revenue: RON694.8m (up 25% from FY 2020). Net income: RON94.7m (up 44% from FY 2020). Profit margin: 14% (up from 12% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 60 percentage points per year, which is a significant difference in performance.
Reported Earnings • Nov 18Third quarter 2021 earnings released: EPS RON0.02 (vs RON0.017 in 3Q 2020)The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: RON172.7m (up 26% from 3Q 2020). Net income: RON13.8m (up 20% from 3Q 2020). Profit margin: 8.0% (down from 8.4% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance.
Reported Earnings • Sep 03Second quarter 2021 earnings released: EPS RON0.016 (vs RON0.011 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: RON167.2m (up 30% from 2Q 2020). Net income: RON11.0m (up 41% from 2Q 2020). Profit margin: 6.6% (up from 6.1% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.
Board Change • Jul 28Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Francois Marchand was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
分析記事 • May 24Zentiva's (BVB:SCD) Solid Earnings May Rest On Weak FoundationsThe recent earnings posted by Zentiva S.A. ( BVB:SCD ) were solid, but the stock didn't move as much as we expected. We...
Reported Earnings • May 19First quarter 2021 earnings released: EPS RON0.034 (vs RON0.049 in 1Q 2020)The company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2021 results: Revenue: RON163.1m (up 6.5% from 1Q 2020). Net income: RON23.6m (down 31% from 1Q 2020). Profit margin: 14% (down from 22% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.
Reported Earnings • Mar 03Full year 2020 earnings released: EPS RON0.088 (vs RON0.082 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: RON602.3m (up 7.7% from FY 2019). Net income: RON61.3m (up 40% from FY 2019). Profit margin: 10% (up from 7.8% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.
分析記事 • Mar 01Zentiva (BVB:SCD) Has Gifted Shareholders With A Fantastic 201% Total Return On Their InvestmentPassive investing in index funds can generate returns that roughly match the overall market. But the truth is, you can...
お知らせ • Jan 29Nanologica AB (publ) Signs Collaboration Agreement with Zentiva for the Use of Nlab Drug Delivery PlatformsNanologica AB (publ) announced a collaboration agreement for the use of the NLAB drug delivery platforms has been signed with Zentiva, a pharmaceutical company operating in Europe and beyond. The aim of this collaboration agreement is to simplify the contract process for future product-specific agreements. The agreement gives Zentiva the right to use the NLAB drug delivery platforms for multiple drug development projects. Project specific agreements will be signed separately under this collaboration agreement. Zentiva is a producer of high-quality and affordable medicines, serving people in Europe and beyond. The Company headquartered in Prague, Czech Republic has a network of productions sites and employs more than 4 500 employees.
分析記事 • Jan 25Zentiva S.A.'s (BVB:SCD) Stock Is Going Strong: Have Financials A Role To Play?Most readers would already be aware that Zentiva's (BVB:SCD) stock increased significantly by 11% over the past three...
Is New 90 Day High Low • Jan 14New 90-day high: RON2.98The company is up 6.0% from its price of RON2.82 on 16 October 2020. The Romanian market is up 16% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 1.0% over the same period.
分析記事 • Dec 18Zentiva S.A. (BVB:SCD) Investors Are Less Pessimistic Than ExpectedWhen close to half the companies in Romania have price-to-earnings ratios (or "P/E's") below 12x, you may consider...